New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 2, 2014
10:01 EDTHUMHumana names Chris Hunter as Chief Strategy Officer
Humana announced that Chris Hunter has been appointed senior vice president and Chief Strategy Officer. In this capacity Hunter will be responsible for leading the company’s strategic planning processes and setting the direction for merger and acquisition, joint venture and other corporate activities. He will assume the role effective Jan. 6. He most recently served as the President of Provider Markets at TriZetto, a Denver-based health information technology firm serving health care providers.
News For HUM From The Last 14 Days
Check below for free stories on HUM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2014
10:51 EDTHUMHealth insurers slide after UnitedHealth results, cautious comments
Shares of a number of health insurers are falling after the largest company in the sector, UnitedHealth (UNH), reported slightly higher than expected first quarter profit but lower than expected revenue. WHAT'S NEW: UnitedHealth's first quarter earnings per share came in at $1.10, versus the consensus outlook of $1.09. The insurer reported revenue of $31.71B, compared with the consensus outlook of $31.99B. Taxes levied by the Affordable Care Act and weak funding of Medicare Advantage by the government weighed on UnitedHealth's earnings, the company stated. Also pushing down the company's earnings was "a very expensive," new Hepatitis C therapy, UnitedHealth stated on its earnings conference call. Hepatitis C treatments cost UnitedHealth hundreds of millions of dollars in the first quarter, the company stated, though it also noted that demand for the treatments should drop going forward as initial pent-up demand for them starts to decline. The company indicated that it was looking to be reimbursed by states for the money it is spending on hepatitis vaccines for Medicaid patients. Meanwhile, UnitedHealth reiterated its fiscal 2014 EPS guidance of $5.40-$5.60 and its fiscal 2014 revenue guidance of $128B-$129B. PRICE ACTION: In mid-morning trading, UnitedHealth sank 3.7% to $75.31. Other health insurers also declined, with WellPoint (WLP) dropping 4% to $91.89, Aetna (AET) falling 3.3% to $67.54, Humana (HUM) declining 2.25% to $106.35, and Health Net (HNT) sliding 1% to $31.74.
April 16, 2014
12:01 EDTHUMHumana, Dignity Health sign agreement
Subscribe for More Information
10:08 EDTHUMUnitedHealth retreats after Citi cuts rating on shares
Subscribe for More Information
April 15, 2014
06:32 EDTHUMPatients paying much more for specialty drugs, NY Times says
The amount that patients with certain diseases must pay for specialty drugs has increased significantly, a research firm reported, according to The New York Times. Meanwhile, consumers' use of health care increased in 2013 for the firm time in three years, the newspaper quoted the firm, the IMS Institute for Healthcare Informatics, as saying. Publicly traded drug makers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded health insurers include AMERIGROUP (AGP), Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Healthspring (HS), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH), WellCare (WCG) and WellPoint (WLP).Reference Link
April 8, 2014
11:02 EDTHUMHumana now sees 2015 CMS Medicare Advantage funding decline of 3%
Subscribe for More Information
10:18 EDTHUMCMS says Medicare Advantage reimbursement to rise in 2015
Subscribe for More Information
09:23 EDTHUMLeerink views final rates as favorable for MA plans
Subscribe for More Information
April 7, 2014
19:13 EDTHUMCMS issues 2015 rate announcement for Medicare Advantage and Part D programs
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use